UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
For the month of August 2025
Commission File Number: 001-41425
金太阳健康科技集团有限公司
(Translation of registrant’s name into English)
Golden Sun Health Technology Group Limited
Room 503, Building C2, No. 1599
Xinjinqiao Road, Pudong New Area
Shanghai, China
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INCORPORATION BY REFERENCE
This Current Report on Form 6-K shall be deemed
to be incorporated by reference into the registration statement on Form
F-1, as amended (Registration Number: 333-285857) of Golden Sun Health Technology Group Limited, a Cayman Islands exempted company
(the “Company”), declared effective by the Securities and Exchange Commission (“SEC”) on March 25,
2025 (“Registration Statement”), and into each prospectus or prospectus supplement outstanding under the Registration
Statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act
of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On August 27, 2025, the Company received formal
notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(1)
(the “Minimum Stockholders’ Equity Rule”) and all other applicable criteria for continued listing on The Nasdaq Capital
Market. Nasdaq will continue to monitor the Company to ensure its ongoing compliance with the Minimum Stockholders’ Equity Rule
and, if at the time of the filing of the Company’s next periodic financial statements the Company does not evidence compliance with
the Minimum Stockholders’ Equity Rule, the Company may again be subject to delisting. In such event, the Staff would provide
written notice of the deficiency the Company, which the Company may appeal to a Nasdaq Hearings Panel.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
| |
Golden Sun Health Technology Group Limited |
| |
|
|
| |
By: |
/s/ Xueyuan Weng |
| |
|
Name: |
Xueyuan Weng |
| |
|
Title: |
Chief Executive Officer |
Date:
August 29, 2025
2
